Development of antibodies and chimeric molecules for cancer immunotherapy (Q36490753)

14 August 2017

1 reference

title

Development of antibodies and chimeric molecules for cancer immunotherapy (English)

1 reference

14 August 2017

1 reference

1

Thomas A Waldmann

1 reference

14 August 2017

John C Morris

2

1 reference

14 August 2017

1 January 2006

1 reference

14 August 2017

Advances in Immunology

1 reference

14 August 2017

90

1 reference

14 August 2017

83-131

1 reference

Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu

14 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Monoclonal antibody therapy of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Antibody-directed enzyme prodrug therapy for cancer: its theoretical basis and application

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Improving the efficacy of antibody-based cancer therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Humanization of an anti-p185HER2 antibody for human cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Engineering antibodies for clinical applications in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

The radioisotope contributes significantly to the activity of radioimmunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Tumor-activated prodrugs--a new approach to cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Complement activation determines the therapeutic activity of rituximab in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Cytokines in cancer pathogenesis and cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

CTLA-4 blockade: unveiling immune regulation

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Radioimmunotherapy of prostatic adenocarcinomas: effects of 131I-labelled E4 antibodies on cells at different depth in DU 145 spheroids

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Transforming growth factor-beta in T-cell biology

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Therapeutic antibodies: magic bullets hit the target.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

REMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1H

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Engineered human IgG antibodies with longer serum half-lives in primates

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Vascular endothelial growth factor and angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Engineered antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Humanised monoclonal antibody therapy for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Tumour biology: herceptin acts as an anti-angiogenic cocktail.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Delivery of molecular and cellular medicine to solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

131I-tositumomab therapy as initial treatment for follicular lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

A phase II multicenter study of CAMPATH-1H antibody in previously treated patients with nonbulky non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Continuous cultures of fused cells secreting antibody of predefined specificity

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Control of homeostasis of CD8+ memory T cells by opposing cytokines.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Enhancement of antitumor immunity by CTLA-4 blockade

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Fas and the art of lymphocyte maintenance

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Targeted cytokines for cancer immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

The EGF receptor family as targets for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Antibody-targeted radiation cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype Antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Advances in interleukin 2 receptor targeted treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

A unique cell surface antigen identifying lymphoid malignancies of B cell origin

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

FcgammaRIV: a novel FcR with distinct IgG subclass specificity

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Humanized CD52 monoclonal antibody campath-1H as first-line treatment in chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

A humanized antibody that binds to the interleukin 2 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Immune inhibitory receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Pharmacokinetics of CAMPATH-1H in BMT patients

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Reshaping human antibodies for therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Introduction: bispecific antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Cardiac dysfunction in the trastuzumab clinical trials experience

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Regulatory T cells in autoimmmunity*.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Hybrid antibodies can target sites for attack by T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Expression of cell surface markers after human B lymphocyte activation

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Primary structure of CD52.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high- and low-grade non-Hodgkin's lymphomas: a multicenter phase I/II study

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Monoclonal antibody therapy for cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Monoclonal antibodies in diagnosis and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

ABCs of radioisotopes used for radioimmunotherapy: alpha- and beta-emitters

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Immunotherapy: past, present and future

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

1 reference

7 January 2021

Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth 213.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult t-cell leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

MTS-conjugated-antiactive caspase 3 antibodies inhibit actinomycin D-induced apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2776%2806%2990003-0

7 January 2021

10.1016/S0065-2776(06)90003-0

Identifiers

DOI

1 reference

14 August 2017

1 reference

PubMed ID

16730262